A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients with Inhibitors
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Concizumab (Primary) ; Eptacog alfa (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Therapeutic Use
- Acronyms explorer™4
- Sponsors Novo Nordisk
- 11 Aug 2017 Status changed from not yet recruiting to recruiting.
- 08 Aug 2017 Planned primary completion date changed from 28 Aug 2018 to 29 Aug 2018.
- 14 Jun 2017 New trial record